FDA Exploring NSAIDs Versus COX-2s; Advisory Meeting Planned In 2005
This article was originally published in The Tan Sheet
Executive Summary
FDA says it still lacks definitive evidence as to whether COX-2 selective agents have a different cardiovascular risk profile than traditional NSAIDs